Healthcare / Drug Manufacturers - Specialty & GenericBSE
$63.00
-4.00 (-5.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $20.9M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$646M
P/E
22.6x
↑EV/EBITDA
12.2x
↑ROE
-2.1%
↓Gross Margin
52.3%
↑Debt/Equity
1.00
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.2%
FCF CAGR
-46.3%
FCF margin
2.5%
FCF / Net income
-1.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $833.8M · net income $-14.2M · FCF $20.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $833.8M | $833.8M | $901.6M | $1.10B | $1.19B |
| Net Income | $-14.2M | $-14.2M | $-17.9M | $66.8M | $64.2M |
| EBITDA | $107.9M | $107.9M | $82.8M | $198.3M | $181.3M |
| EPS | -1.38 | -1.38 | -1.74 | 6.52 | 6.26 |
| Gross Margin | 52.3% | 52.3% | 44.4% | 53.7% | 55.4% |
| Operating Margin | 8.0% | 8.0% | -1.4% | 11.1% | 13.8% |
| Net Margin | -1.7% | -1.7% | -2.0% | 6.0% | 5.4% |
| Balance Sheet | |||||
| Debt/Equity | 1.00 | 1.00 | 0.95 | 0.64 | 0.69 |
| Cash Flow | |||||
| Free Cash Flow | $20.9M | $20.9M | $-258.6M | $32.7M | $134.7M |
| Returns | |||||
| ROE | -2.1% | -2.1% | -2.6% | 11.9% | 12.9% |
| Valuation | |||||
| P/E | 22.58 | 22.58 | — | 10.11 | 10.89 |
| EV/EBITDA | 12.20 | 12.20 | 15.57 | 5.18 | 5.75 |
| P/B | 0.96 | 0.96 | 0.94 | 1.21 | 1.40 |
| Growth & Yield | |||||
| Revenue Growth | -7.5% | -7.5% | -18.4% | -7.3% | — |
| EPS Growth | 20.7% | 20.7% | -126.7% | 4.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.74 → -1.38
Residual
-22.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.